Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is demonstrating a robust pipeline, particularly with its product candidate BT1718, as indicated by positive feedback from key opinion leaders (KOLs) who recognize its competitive advantages over established therapies like Padcev. The company's innovative Bicycles, designed to target oncology indications with significant unmet medical needs, position it favorably within an evolving biopharmaceutical landscape. Additionally, BCYC's focus on delivering safe and effective outcomes while maintaining lower system costs enhances its potential for generating substantial revenue, primarily from its stronger market presence in the United States.

Bears say

Bicycle Therapeutics PLC has faced significant stock pressure, with shares down 45% year-to-date, primarily due to investor concerns over equivocal clinical data amid a challenging market environment. The risk of safety issues or poor efficacy related to its product candidate Zelenectide highlights potential for further downside, estimated at 25% if these concerns materialize. Additionally, the stock is currently trading below cash, indicating investor skepticism regarding the company's unique approach and the viability of its pipeline in oncology.

BCYC has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 10 analysts, BCYC has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.